Samsung Biologics revenue and financials

207940 · KRX · KRW

₩1,423,000.00Change from previous close: +0.85%Absolute change: +₩12,000.00

Close · November 16, 2026

In the fiscal year ended December 2025, Samsung Biologics reported revenue of ₩4.56T (+30.31% year over year). Net income was ₩1.78T, a net margin of 39.2%.

Annual revenue · 2025: ₩4.56T
  1. ₩294.62B2016
  2. ₩464.63B2017
  3. ₩535.81B2018
  4. ₩701.59B2019
  5. ₩1.16T2020
  6. ₩1.57T2021
  7. ₩3T2022
  8. ₩3.69T2023
  9. ₩3.5T2024
  10. ₩4.56T2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+30.31%
2025 vs 2024
Net income growth
+64.71%
2025 vs 2024
Net margin
39.2%
2024: 31.0%

How Samsung Biologics is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of KRW; per-share values in KRW; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue4,556,9723,497,1463,694,5893,001,2951,568,0071,164,777701,592535,806464,629294,622
Cost of revenue2,056,1311,798,0931,900,0801,540,526844,657751,189510,060390,778333,207269,097
Gross profit2,500,8411,699,0531,794,5091,460,769723,350413,588191,532145,028131,42325,525
Selling, general and administrative356,447306,667556,931402,863174,488110,00988,87873,16954,95148,672
Research and development37,18136,71181,58845,884954—————
Operating income2,069,2211,321,3661,113,680983,627537,309292,78791,74255,67965,979-30,423
EBIT2,069,2211,321,3661,113,680983,627537,309292,78791,74255,67965,979-30,423
EBITDA2,702,8581,920,4681,603,4621,291,892699,098436,475224,627141,368131,72925,517
Interest expense29,17134,12381,59664,06414,70716,08625,61515,8395,68419,254
Pre-tax income2,118,6311,384,8691,119,9871,009,025561,283265,992155,435302,976-115,995-230,901
Income tax504,301344,567262,296210,968167,69325,017-47,46978,867-19,023-54,078
Net income1,784,3521,083,316857,691798,056393,589240,975202,904224,109-96,972-176,823
Net income to common shareholders1,614,3301,040,302857,691798,056393,589240,975202,904224,109-96,972-176,823
Basic EPS37,040.3922,473.1118,528.2717,592.799,146.195,599.754,715.075,207.83-2,253.43-4,789.48
Diluted EPS37,040.3922,473.1118,528.2717,577.119,146.195,599.754,715.075,207.83-2,253.43-4,789.48
Average shares (basic)43.646.346.345.443.043.043.043.043.036.9
Average shares (diluted)43.646.346.345.443.043.043.043.043.036.9

Companies in the group: same industry, similar size